Stock News

Penumbra, Inc. (PEN) Reaches $155.80 52-Week High; Ardelyx (ARDX) Sellers Decreased By 5.21% Their Shorts

Penumbra, Inc. (NYSE:PEN) Logo

Ardelyx Inc (NASDAQ:ARDX) had a decrease of 5.21% in short interest. ARDX’s SI was 1.67M shares in May as released by FINRA. Its down 5.21% from 1.76 million shares previously. With 314,100 avg volume, 5 days are for Ardelyx Inc (NASDAQ:ARDX)’s short sellers to cover ARDX’s short positions. The SI to Ardelyx Inc’s float is 6.05%. The stock increased 0.44% or $0.025 during the last trading session, reaching $5.725. About 61,208 shares traded. Ardelyx, Inc. (NASDAQ:ARDX) has declined 60.67% since May 17, 2017 and is downtrending. It has underperformed by 72.22% the S&P500.

The stock of Penumbra, Inc. (NYSE:PEN) hit a new 52-week high and has $165.15 target or 6.00% above today’s $155.80 share price. The 6 months bullish chart indicates low risk for the $5.34 billion company. The 1-year high was reported on May, 17 by If the $165.15 price target is reached, the company will be worth $320.28 million more. The stock increased 1.27% or $1.95 during the last trading session, reaching $155.8. About 108,989 shares traded. Penumbra, Inc. (NYSE:PEN) has risen 41.68% since May 17, 2017 and is uptrending. It has outperformed by 30.13% the S&P500.

Among 7 analysts covering Ardelyx Inc (NASDAQ:ARDX), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ardelyx Inc had 16 analyst reports since August 18, 2015 according to SRatingsIntel. The company was maintained on Monday, August 28 by Cantor Fitzgerald. The firm has “Overweight” rating given on Thursday, October 12 by Cantor Fitzgerald. The stock has “Buy” rating by BTIG Research on Tuesday, September 22. The firm earned “Buy” rating on Wednesday, August 10 by Citigroup. The rating was initiated by BTIG Research on Friday, December 18 with “Buy”. Wedbush maintained Ardelyx, Inc. (NASDAQ:ARDX) on Thursday, October 12 with “Buy” rating. Ladenburg Thalmann initiated Ardelyx, Inc. (NASDAQ:ARDX) rating on Thursday, March 31. Ladenburg Thalmann has “Buy” rating and $21 target. The firm earned “Buy” rating on Friday, October 13 by BTIG Research. On Wednesday, March 9 the stock rating was maintained by JMP Securities with “Market Outperform”. The firm has “Buy” rating by Cantor Fitzgerald given on Friday, March 16.

Ardelyx, Inc. develops and sells therapeutics for the treatment of cardio renal and gastrointestinal diseases in the United States. The company has market cap of $272.53 million. The Company’s lead product candidate is tenapanor, which is in Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It currently has negative earnings. The firm is also developing RDX7675, which is in Phase III clinical trial for the treatment of people with hyperkalemia; and RDX8940 in Phase I clinical trial for the treatment of patients with NASH and other gastrointestinal indications.

Another recent and important Ardelyx, Inc. (NASDAQ:ARDX) news was published by which published an article titled: “Ardelyx Looks Cheap But Not Without Risk” on May 17, 2018.

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company has market cap of $5.34 billion. The firm offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, PX SLIM, and Velocity brands; aspiration based thrombectomy systems and accessory devices under the Penumbra System brand; and revascularization device for mechanical thrombectomy under the 3D brand. It has a 1198.46 P/E ratio. It also provides neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400 and Penumbra SMART Coil brands; and neurovascular stents for stent-assisted coiling in large and wide-neck aneurysms under the LIBERTY Stent brand.

Analysts await Penumbra, Inc. (NYSE:PEN) to report earnings on August, 14. They expect $0.03 EPS, up 160.00% or $0.08 from last year’s $-0.05 per share. PEN’s profit will be $1.03M for 1298.33 P/E if the $0.03 EPS becomes a reality. After $0.06 actual EPS reported by Penumbra, Inc. for the previous quarter, Wall Street now forecasts -50.00% negative EPS growth.

Another recent and important Penumbra, Inc. (NYSE:PEN) news was published by which published an article titled: “Penumbra’s (PEN) CEO Adam Elsesser on Q1 2018 Results – Earnings Call Transcript” on May 12, 2018.

Ardelyx, Inc. (NASDAQ:ARDX) Ratings Chart

Leave a Reply

Your email address will not be published. Required fields are marked *